Zobrazeno 1 - 10
of 6 552
pro vyhledávání: '"CAR T cell"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Few studies evaluated patient-reported outcomes (PROs) for patients with hematologic malignancies receiving with Chimeric Antigen Receptor T (CAR-T) cell therapy. We performed a systematic review and meta-analysis to evaluate the benefits of
Externí odkaz:
https://doaj.org/article/d37c34b1d0d149ea9f410408e3c3ceb8
Autor:
Prasanna Srinivasan Ramalingam, T. Premkumar, Vino Sundararajan, Md Sadique Hussain, Sivakumar Arumugam
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Mutant KRAS promotes the proliferation, metastasis, and aggressiveness of various cancers including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal adenocarcinoma (CRC) respectively. Mutant KRAS th
Externí odkaz:
https://doaj.org/article/b81ba153528748408459b77d85bb3ba4
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-19 (2024)
Abstract In recent years, immunotherapy has developed rapidly as a new field of tumour therapy. However, the efficacy of tumour immunotherapy is not satisfactory due to the immune evasion mechanism of tumour cells, induction of immunosuppressive tumo
Externí odkaz:
https://doaj.org/article/c59c35806000402bb07f80262594176d
Autor:
Xiaoxi Zhou, Qiuxia Yu, Zigang Dai, Jue Wang, Chunrui Li, Liang Huang, Yicheng Zhang, Yang Cao
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)
Abstract Relapsed/refractory (R/R) primary and secondary central nervous system lymphomas (PCNSL, SCNSL) are associated with short survival and represent an unmet need, requiring novel effective strategies. We retrospectively compared the safety and
Externí odkaz:
https://doaj.org/article/07e8dc0d486f4f0ebba53ec5ac6f86fd
Autor:
Xianjun Li, Tianjun Chen, Xuehan Li, Hanyu Zhang, Yingjing Li, Shuyuan Zhang, Shengnan Luo, Tongsen Zheng
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2024)
Abstract Chimeric antigen receptor (CAR) T cell therapy, which targets tumors with high specificity through the recognition of particular antigens, has emerged as one of the most rapidly advancing modalities in immunotherapy, demonstrating substantia
Externí odkaz:
https://doaj.org/article/856a1647235f462793d6ed0e80614606
Autor:
Fatemeh Nasiri, Yasaman Asaadi, Farzaneh Mirzadeh, Shahrokh Abdolahi, Sedigheh Molaei, Somayeh Piri Gavgani, Fatemeh Rahbarizadeh
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-31 (2024)
Abstract Multiple myeloma (MM) is a hematological cancer characterized by the abnormal proliferation of plasma cells. Initial treatments often include immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs). Desp
Externí odkaz:
https://doaj.org/article/6b0a7e5a21414a61a1cddb7dba91e414
Autor:
Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan, Chao Wang, Xin Zheng, Yi-Lun Zhang, Hao-Xu Yang, Wen Wu, Peng-Peng Xu, Shu Cheng, Emmanuel Bachy, Pierre Sesques, Nicolas Jacquet-Francillon, Xu-Feng Jiang, Wei-Li Zhao, Li Wang
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-7 (2024)
Abstract Chimeric antigen receptor T (CAR-T) cell therapy has greatly improved the prognosis of relapsed and refractory patients with large B-cell lymphoma (LBCL). Early identification and intervention of patients who may respond poorly to CAR-T cell
Externí odkaz:
https://doaj.org/article/4b9725d563dd402392bbdf87337f7ad2
Autor:
Krasimira Aleksandrova, Jana Leise, Christoph Priesner, Murat Aktas, Michael Apel, Mario Assenmacher, Iris Bürger, Anne Richter, Pia Altefrohne, Christine Schubert, Astrid Holzinger, Markus Barden, Valerie Bezler, Michael von Bergwelt-Baildon, Peter Borchmann, Lilia Goudeva, Wolfgang Glienke, Lubomir Arseniev, Ruth Esser, Hinrich Abken, Ulrike Koehl
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionPoint-of-care (POC) manufacturing of chimeric antigen receptor (CAR) modified T cell has expanded rapidly over the last decade. In addition to the use of CD19 CAR T cells for hematological diseases, there is a growing interest in targetin
Externí odkaz:
https://doaj.org/article/f6589c518506495e91a9217ebb7da6b4
Autor:
Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the
Externí odkaz:
https://doaj.org/article/613627563fa145bcad4718e937c66eed
Autor:
Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Dhuha Ali Al-Adhami, Mike Sathekge, Henry Hee-Seung Bom, Mohammad Ma’koseh, Asem Mansour, Hikmat Abdel-Razeq, Kamal Al-Rabi, Enrique Estrada-Lobato, Maysaa Al-Hussaini, Ismail Matalka, Zaid Abdel Rahman, Stephano Fanti
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundChimeric antigen receptor (CAR) T-cell therapy has attracted considerable attention since its recent endorsement by the Food and Drug Administration, as it has emerged as a promising immunotherapeutic modality within the landscape of oncolo
Externí odkaz:
https://doaj.org/article/5f4d6ee0c48745a5bae3df3dad0ee55a